Conference Details - Agenda

View all Conferences

Continuing Education Information

Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Current Trends in Leukemia, Lymphoma, and Myeloma

Robert H. Lurie Medical Research Center Baldwin Auditorium
Chicago, IL
January 16, 2009

Friday, January 16, 2009

7:30 am Continental Breakfast
Steven Rosen
7:50 am Introductions and Presession Survey
Lymphoma
Moderator: Steven Rosen
8:05 am Management of Aggressive Lymphoma
Leo I. Gordon
8:35 am New Insights on Low-Grade and T-Cell Non-Hodgkin Lymphoma
Andrew M. Evens
9:05 am Panel/Case-Based Discussion
9:35 am Break
Myeloma
Moderator: Steven Rosen
9:50 am Progress in Multiple Myeloma
Seema Singhal
10:20 am Question-and-Answer Session/Case-Based Discussion
Myeloid Malignancies
Moderator: Steven Rosen
10:50 am Updates on Chronic Myeloid Leukemia
Jessica K. Altman
11:20 am Lunch
12:20 pm Emerging Agents for Myelodysplastic Syndromes
Olga Frankfurt
12:50 pm Panel/Case-Based Discussion
Benign Hematologic Disorders
Moderator: Steven Rosen
1:20 pm Update on Novel Therapies for Idiopathic Thrombocytopenic Purpura and Other Benign Hematologic Disorders
Anaadriana Zakarija
1:50 pm Question-and-Answer Session/Case-Based Discussion
2:20 pm Break
Leukemia
Moderator: Steven Rosen
2:35 pm What’s New in the Management of Chronic Lymphocytic Leukemia?
Steven Rosen
3:05 pm Treatment Options for the Acute Leukemias
Martin S. Tallman
3:35 pm Postsession Survey and Panel/Case-Based Discussion
4:05 pm Adjourn

Educational Grants

An educational grant for this activity was provided by:


  1. GlaxoSmithKline
  2. Celgene Corporation
  3. Genentech BioOncology/
    Biogen Idec
  4. Millennium Pharmaceuticals
  5. Eisai, Inc.